China Isotope & Radiation Corporation has issued a profit warning for the year ended 31 December 2025, expecting a significant decline in its financial performance. The company's net profit is projected to be approximately RMB611 million to RMB655 million, reflecting a year-on-year decrease of about 25% to 30%. Profit attributable to equity shareholders is anticipated to be around RMB302 million to RMB322 million, representing a decrease of approximately 20% to 25% compared to the previous year. The decline in revenue is mainly attributed to reduced sales in the nuclear medical equipment segment, while the decrease in profit is primarily due to supplementary tax payments and late fees incurred by the subsidiary Shenzhen Zhonghe Headway Bio-Sci & Tech Co., Ltd. The company reports that its business operations remain normal.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China Isotope & Radiation Corporation published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260212-12023473), on February 12, 2026, and is solely responsible for the information contained therein.